Daylight photodynamic therapy: where and when is it possible?

The article focuses on adoption of daylight photodynamic therapy (dPDT) for treatment of sun damage among patients with field cancerization of actinic keratoses (AKs). Topics discussed include usage of methyl aminolevolinate (MAL) as prodrug for photosensitzer protoporphyrin IX (PpIX); analysis of different in pain sensation with the therapy in comparison to conventional methods that leads to reactive oxygen species (ROS) damage; and consideration of dosimetry usage for dPDT.